P3 Health PartnersPIII
PIII
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
7.41% less ownership
Funds ownership: 19.83% [Q3] → 12.42% (-7.41%) [Q4]
15% less funds holding
Funds holding: 46 [Q3] → 39 (-7) [Q4]
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
63% less capital invested
Capital invested by funds: $12.4M [Q3] → $4.57M (-$7.81M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for PIII.
Financial journalist opinion
Based on 5 articles about PIII published over the past 30 days
Neutral
Seeking Alpha
4 days ago
P3 Health Partners Inc. (PIII) Q4 2024 Earnings Conference Call Transcript
P3 Health Partners Inc. (NASDAQ:PIII ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Ryan Halsted - IR Aric Coffman - CEO Leif Pedersen - CFO Amir Bacchus - Chief Medical Officer Conference Call Participants Josh Raskin - Nephron Research David Larsen - BTIG Ryan Langston - TD Cowen Jack Senft - William Blair Operator Good day and welcome to the P3 Health Partners' Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Negative
Zacks Investment Research
4 days ago
P3 Health Partners Inc. (PIII) Reports Q4 Loss, Lags Revenue Estimates
P3 Health Partners Inc. (PIII) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.22 per share a year ago.
Neutral
Business Wire
4 days ago
P3 Health Partners Announces Fourth Quarter and Full Year 2024 Results
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient- centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and affirmed its 2025 guidance. “Our business model remains fundamentally strong as we continue to deliver member and top-line growth, quality outcomes, and provider retention,” said Aric Coffman, CEO of P3. “With the $130M+.
Neutral
Business Wire
2 weeks ago
P3 Health Partners to Report Fourth Quarter and Full Year 2024 Financial Results on March 27
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for the fourth quarter and full year 2024 on March 27, 2025. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health Fourth Quarter Earnings Conference Cal.
Positive
Zacks Investment Research
3 weeks ago
P3 Health Partners (PIII) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
P3 Health Partners (PIII) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Neutral
Business Wire
1 month ago
P3 Health Partners to Participate in the TD Cowen 45th Annual Health Care Conference
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that it will participate in the upcoming TD Cowen 45th Annual Health Care Conference in Boston, Massachusetts. Management is scheduled to host investor meetings on Wednesday March 5th, 2025. About P3 Health Partners (NASDAQ: PIII): P3 Health Partners Inc. is a leading population health management company committed to transfor.
Neutral
Business Wire
1 month ago
P3 Health Partners Provides Preliminary 2025 Guidance and Announces Proposed Financing Transaction
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered, physician-led population health management company, is targeting profitability in 2025, with initial revenue guidance for the year of $1.350 billion to $1.500 billion and Adjusted EBITDA of negative ($35) million to $5 million. “The execution of our previously announced $130+ million EBITDA growth initiatives is going as planned, most of which have been actioned and implemented.
Neutral
GlobeNewsWire
1 month ago
Kuehn Law Encourages Investors of P3 Health Partners Inc. to Contact Law Firm
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of P3 Health Partners Inc. (NASDAQ: PIII) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Neutral
Business Wire
2 months ago
P3 Health Partners to Present at the 43rd Annual J.P. Morgan Healthcare Conference
HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced it will participate at the upcoming J.P. Morgan Healthcare Conference in San Francisco, California. Management will give a presentation on Tuesday, January 14, 2024, at 7:30 AM Pacific Time. A webcast of the presentation will be available on P3's Investor Relations Website at https://ir.p3hp.org/. A replay wi.
Neutral
PRNewsWire
3 months ago
Kuehn Law Encourages Investors of P3 Health Partners Inc. to Contact Law Firm
NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of P3 Health Partners Inc. (NASDAQ: PIII) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Charts implemented using Lightweight Charts™